Materialise's Q2 results were weak due to European automotive headwinds and macro uncertainty. Materialise's Medical segment continues to thrive, and its Software business is nearly done transitioning to a recurring revenue model. Medical segment strength justifies a higher valuation, but the Manufacturing business must stabilize before the stock can meaningfully re-rate.
LEUVEN, Belgium--(BUSINESS WIRE)--Materialise NV (NASDAQ:MTLS), a leading provider of additive manufacturing and medical software and of sophisticated 3D printing services, today announced its financial results for the second quarter ended June 30, 2025. Highlights – Second Quarter 2025 Total consolidated revenue decreased 5.8% to 64,831 kEUR compared to the corresponding 2024 period; however a...
I rate Materialise a 'buy' with a fair value of $8.83, driven by its unique integrated 3D printing software and hardware solutions. Materialise's strategic focus on software and medical segments strengthens its competitive edge, with medical now 47% of revenue and growing double digits. Recurring software revenue exceeds 80% in its segment, supporting margin expansion, customer retention, and r...
LEUVEN, Belgium--(BUSINESS WIRE)--Materialise NV (NASDAQ: MTLS), a leading provider of additive manufacturing software and of sophisticated 3D printing services, today announced that it will release financial results for the second quarter ended June 30, 2025 on Thursday, July 24, 2025 at 6:30 a.m. ET/12:30 p.m. CET. Senior management will hold a conference call to discuss the second quarter 20...
LEUVEN, Belgium, May 16, 2025 (GLOBE NEWSWIRE) -- Materialise NV (NASDAQ:MTLS), a leading provider of additive manufacturing software and sophisticated 3D printing solutions, today announced that it will host its Annual General Shareholders' Meeting (AGM) on Tuesday, June 3, 2025, at 10:00 am CET.
While Materialise's Q1 results were mixed they exceeded low investor expectations, with the company's Medical segment continuing to excel. Market conditions are likely to remain challenging, but lower energy costs and increased defense spending in Europe could help to offset this. Materialise's Medical segment alone more than justifies its current market capitalization.
Materialise NV (NASDAQ:MTLS ) Q1 2025 Earnings Conference Call April 24, 2025 8:30 AM ET Company Participants Harriet Fried - Alliance Advisors, IR Brigitte de Vet - Chief Executive Officer Koen Berges - Chief Financial Officer Conference Call Participants Troy Jensen - Cantor Fitzgerald Operator Good day and thank you for standing by. Welcome to the First Quarter 2025 Materialise Financial Res...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.